nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Chronic obstructive pulmonary disease: new therapies and old needs
|
Hopkinson, Nicholas S |
|
|
13 |
3 |
p. 193-194 |
artikel |
2 |
Correction to Lancet Respir Med 2025; 13: 244–55
|
|
|
|
13 |
3 |
p. e19 |
artikel |
3 |
Correction to Lancet Respir Med 2025; 13: 256–71
|
|
|
|
13 |
3 |
p. e19 |
artikel |
4 |
Corticosteroids in community-acquired pneumonia: a step forward, but questions remain
|
Reyes, Luis Felipe |
|
|
13 |
3 |
p. 191-193 |
artikel |
5 |
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
|
Bhatt, Surya P |
|
|
13 |
3 |
p. 234-243 |
artikel |
6 |
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial
|
Castro, Mario |
|
|
13 |
3 |
p. 208-220 |
artikel |
7 |
Home-based monitoring in chronic respiratory diseases: in search of Panacea
|
Roche, Nicolas |
|
|
13 |
3 |
p. e17-e18 |
artikel |
8 |
How Glasgow's 1957 tuberculosis screening programme could help countries today
|
Ranscombe, Peter |
|
|
13 |
3 |
p. 203-204 |
artikel |
9 |
Idiopathic inflammatory myopathies related lung disease in adults
|
Sehgal, Sameep |
|
|
13 |
3 |
p. 272-288 |
artikel |
10 |
Management and mechanisms of eosinophil action in asthma: mind the gap?
|
Russell, Richard E K |
|
|
13 |
3 |
p. 190-191 |
artikel |
11 |
On the front lines of the sepsis crisis: hurdles faced by sepsis researchers, survivors, and family advocates
|
Duda, Jackie |
|
|
13 |
3 |
p. 205-206 |
artikel |
12 |
Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials
|
Smit, Jim M |
|
|
13 |
3 |
p. 221-233 |
artikel |
13 |
Social and environmental determinants of health inequities in childhood asthma
|
Alsulami, Saleh |
|
|
13 |
3 |
p. 197-199 |
artikel |
14 |
Spirometry—one size doesn't fit all
|
The Lancet Respiratory Medicine, |
|
|
13 |
3 |
p. 189 |
artikel |
15 |
Stubble: the Farmer's Bane
|
Burki, Talha |
|
|
13 |
3 |
p. 207 |
artikel |
16 |
Vaccine policy experts concerned about second Trump Administration
|
Furlow, Bryant |
|
|
13 |
3 |
p. 200-201 |
artikel |
17 |
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
|
Hoppe, Jordana E |
|
|
13 |
3 |
p. 244-255 |
artikel |
18 |
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials
|
Keating, Claire |
|
|
13 |
3 |
p. 256-271 |
artikel |
19 |
What does the expanding CFTR modulator programme mean for people with cystic fibrosis?
|
Southern, Kevin W |
|
|
13 |
3 |
p. 195-197 |
artikel |
20 |
Wildfires in southern California: concerns for lung health
|
Burki, Talha |
|
|
13 |
3 |
p. 202 |
artikel |